Diya Dhakal

This study shows that Prostaglandin E2 reverses myofibroblast differentiation in EoE via the cAMP/YAP/THBS-1 pathway, suggesting it as a potential treatment for fibrostenotic EoE.

SUMMIT traces mitochondrial mutations in human tissues to identify spatially localized clones and their transcriptomic profiles.

This study identifies FOXM1 as a key driver of epithelial disruption in EoE, showing that its inhibition restores differentiation, reduces hyperplasia, and improves barrier function.